KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Medtronic (MDT) Cash & Equivalents (2016 - 2026)

Medtronic's Cash & Equivalents history spans 13 years, with the latest figure at $1.1 billion for Q1 2026.

  • For Q1 2026, Cash & Equivalents fell 7.5% year-over-year to $1.1 billion; the TTM value through Jan 2026 reached $1.1 billion, down 7.5%, while the annual FY2025 figure was $2.2 billion, 72.74% up from the prior year.
  • Cash & Equivalents for Q1 2026 was $1.1 billion at Medtronic, down from $1.3 billion in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $4.8 billion in Q4 2022 and bottomed at $1.1 billion in Q1 2026.
  • The 5-year median for Cash & Equivalents is $1.4 billion (2024), against an average of $2.1 billion.
  • The largest annual shift saw Cash & Equivalents crashed 72.85% in 2023 before it surged 72.74% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $4.8 billion in 2022, then plummeted by 72.85% to $1.3 billion in 2023, then rose by 6.33% to $1.4 billion in 2024, then decreased by 8.03% to $1.3 billion in 2025, then fell by 10.53% to $1.1 billion in 2026.
  • Per Business Quant, the three most recent readings for MDT's Cash & Equivalents are $1.1 billion (Q1 2026), $1.3 billion (Q4 2025), and $1.3 billion (Q3 2025).